GSK plc vs MasterCard Inc — how do they compare? GSK plc trades at $50.28 (market cap $102.60B), while MasterCard Inc trades at $556.95 (market cap $491.83B). The key difference: MasterCard Inc is far larger — about 4.8× GSK plc's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | MA | |
|---|---|---|
Market Cap | $102.60B | $491.83B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $598.96 |
52-Week Low | $38.22 | $471.55 |
Enterprise Value | $123.04B | $504.86B |
Dividend Yield | 3.57% | 0.62% |
Volume | — | 4,635,698 |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Mastercard (MA) trades at $563.17, showing stability with a slight 0.04% daily gain. The stock exhibits strong fundamentals, with Q2 2026 EPS beating expectations at $5.04 versus $4.77, and maintains robust profitability with a 46.34% net income margin. Technical indicators signal a bullish trend, supported by moving averages, while analyst consensus is overwhelmingly positive with a $660.85 price target. Recent news highlights institutional acquisitions and strategic initiatives in AI and digital inclusion.
Outlook remains favorable driven by consistent earnings beats and revenue growth, though risks include competitive pressures from emerging payment technologies like stablecoins and high valuation multiples. The stock presents a growth opportunity with solid institutional backing, but investors should monitor execution on innovation and macroeconomic factors affecting consumer spending.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →